http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101925020-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S514-909 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S514-866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-328 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-332 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2017-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101925020-B1 |
| titleOfInvention | Pharmaceutical composition for metabolic disease comprising expression or activity inhibitor of MKRN1 as an active ingredient |
| abstract | The present invention relates to a pharmaceutical composition for the prevention and treatment of metabolic diseases, which contains an expression or activity inhibitor of MKRN1 as an active ingredient. The MKRN1 of the present invention is an E3-linking enzyme (E3-linking enzyme) for ubiquitinating AMPKα, ligase, which degrades AMPK protein. Thus, inhibition of MKRN1 expression can restore AMPK expression and activity levels. In addition, since it can exhibit an improvement effect on obesity, diabetes and fatty liver by knockout of MKRN1 expression and knockout of MKRN1 in a mouse model in which obesity, diabetes and fatty liver are induced by high fat diet, the expression or activity of MKRN1 of the present invention An inhibitor can be usefully used as an effective ingredient of a composition for preventing and treating metabolic diseases. |
| priorityDate | 2017-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 252.